AXIM Biotechnologies, Inc. has announced the engagement of 624 Advisors, owned and managed by Dr. Alan J. Touch, as Chief Medical & Regulatory Affairs Advisor. This strategic move provides the diagnostic and biotechnology company with enhanced technical continuity and regulatory depth during a pivotal stage of development. Dr. Touch brings more than three decades of global leadership across diagnostics, medical devices, pharmaceuticals, and digital health, positioning him as a preeminent expert in in vitro diagnostics and companion diagnostics.
The engagement is particularly significant because Dr. Touch is the original co-inventor of the first ocular diagnostic technologies acquired by AXIM. His inventor-level understanding of lactoferrin and immunoassay diagnostics creates unique alignment with AXIM's current efforts. This background reduces the company's reliance on external consultants while accelerating readiness for commercialization and global growth. Dr. Touch's experience includes serving as Principal Strategist for Ophthalmology, Medical Devices and Diagnostics at INC Research (Syneos Health) and heading Clinical Affairs at Bausch & Lomb.
Catalina Valencia, President and CEO of AXIM Biotechnologies, emphasized the importance of this addition to the company's R&D and regulatory team. "Dr. Touch uniquely combines inventor-level knowledge of our technology with significant senior level experience in FDA regulation, ISO quality systems, clinical development, and manufacturing readiness," said Valencia. His involvement strengthens AXIM's regulatory strategy, quality foundation, and clinical execution while positioning the company for efficient global expansion and long-term operational scale.
This engagement comes as AXIM advances toward key regulatory and commercial milestones, including upcoming FDA 510(k) submissions and international regulatory expansion. Dr. Touch's advisory role is designed to provide highly qualified support across these areas while helping establish a robust quality and manufacturing infrastructure. His deep experience across FDA, EU MDR/IVDR, and global regulatory frameworks will be particularly valuable as the company navigates complex international markets.
Dr. Touch expressed his commitment to advancing technology he originally helped develop, stating, "AXIM is building a strong foundation for market-sensitive and aware regulatory excellence and clinical credibility for its products." He looks forward to supporting the scientific, marketing and operational team as they advance key submissions, strengthen quality systems, and prepare for long-term manufacturing and commercial success. For more information about AXIM's diagnostic technologies, visit https://www.aximbiotech.com.
The strategic engagement represents a critical step in AXIM's development timeline, providing the company with proven leadership in regulatory affairs, quality systems, clinical development, and manufacturing scale-up. As the company prepares for commercialization, Dr. Touch's knowledge of milestone-based product development methodology will help optimize AXIM's value proposition in competitive diagnostic markets. This move demonstrates AXIM's commitment to building internal expertise while maintaining focus on regulatory compliance and clinical validation for its TearScan® platform and other diagnostic solutions.
